STOCK TITAN

Immutep - IMMP STOCK NEWS

Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.

Overview of Immutep Ltd

Immutep Ltd is a globally active biotechnology company committed to advancing immunotherapy for both cancer and autoimmune diseases. Leveraging its expertise in immuno-oncology and innovative LAG-3 technology, the company has positioned itself as a specialized entity in personalized bio-therapeutic products. With dual listings on the Australian Stock Exchange and Nasdaq, Immutep demonstrates a robust international presence and a solid foundation in research and development.

Core Technology and Therapeutic Approach

The hallmark of Immutep’s approach is its focus on the LAG-3 immune control mechanism, a critical regulator of the T cell immune response. By modulating this pathway, Immutep aims to enhance the body’s natural ability to fight cancer and potentially address autoimmune conditions. This technology underpins the company’s strategic pipeline and sets a high standard for clinical precision and targeted therapy development.

Product Pipeline and Clinical Development

Immutep’s product portfolio is centered around its most advanced candidate, IMP321, which functions as a T cell immunostimulatory factor. This therapy is designed for integration into cancer chemoimmunotherapy protocols and has achieved significant clinical milestones in early phase trials. In addition to IMP321, the company is developing IMP701, a blocking anti-LAG-3 antibody candidate in early clinical evaluation, and CVac, a personalized immunocellular strategy under investigation for epithelial cancers. These development efforts illustrate a diverse and forward-looking approach that integrates both innovation and strategic collaboration.

Global Operations and Strategic Collaborations

Operating primarily from Australia, Immutep extends its influence across global markets, supported by strong regulatory compliance and research proficiency. Strategic partnerships with large pharmaceutical firms reinforce its pipeline development, enabling access to advanced clinical platforms and shared expertise. The company’s qualification for significant research tax incentives in both Europe and Australia underscores its commitment to high-caliber R&D and validates the commercial and scientific merits of its initiatives.

Industry Position and Business Model

Within the competitive landscape of biotechnology, Immutep differentiates itself by combining deep scientific expertise with a focused therapeutic strategy. Its business model hinges on collaborative partnerships, clinical innovation, and a targeted approach to harnessing LAG-3 mediated immune modulation. Investors and industry observers appreciate the rigorous clinical frameworks employed by the company, which underpin its potential to offer novel therapeutic modalities in the area of cancer treatment and beyond.

Research and Development Excellence

Immutep’s strategic emphasis on research and development is reflected in its participation in international R&D incentive programs. These initiatives not only provide substantial financial support for its clinical trials but also affirm the company’s adherence to high industry standards and scientific integrity. This relentless focus on innovation is at the core of Immutep’s operational ethos, ensuring that its immunotherapeutic solutions are developed in a rigorous and transparent environment.

Conclusion

In summary, Immutep Ltd stands as a key player in the biotechnology industry, with a specific focus on immunotherapy modalities for cancer and autoimmune diseases. Its reliance on advanced LAG-3 technology, comprehensive product pipeline, and robust global partnerships collectively fortify its standing in the competitive landscape. The company’s commitment to R&D excellence and transparent clinical strategies provides a rich source of insight for those seeking to understand a pioneering approach in modern biotechnology.

Rhea-AI Summary

Immutep presented promising data from the safety lead-in phase of their AIPAC-003 Phase II/III trial at the ESMO Breast Cancer Congress 2024. The trial, combining 90mg efti with paclitaxel, showed a 50% overall response rate and a 100% disease control rate in six metastatic breast cancer patients. Notably, one patient achieved a complete response which is ongoing with efti monotherapy. The combination has been well tolerated with no severe adverse events. Higher efti concentrations were observed, remaining pharmacologically active up to 96 hours post-administration. The randomized Phase II portion continues, with more data expected in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
-
Rhea-AI Summary

Immutep has reported positive initial clinical data from the Phase II EFTISARC-NEO trial, combining efti with radiotherapy and pembrolizumab in soft tissue sarcoma patients. The trial showed very good pathologic responses rarely seen with standard therapies, with 67% of patients having near-complete responses. This novel triple combination was well tolerated, with no new safety concerns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
-
Rhea-AI Summary

Immutep provides an update on its product candidates development, including positive clinical data in breast cancer and head and neck squamous cell carcinoma patients, progress in various phase II and III trials, appointment of a new director, and financial summary. The Company remains well-funded with a cash balance of approximately $95.4 million as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
Rhea-AI Summary
Immutep announces positive preliminary topline results from Cohort B of the TACTI-003 Phase IIb trial, showing a 26.9% response rate in first-line head and neck squamous cell carcinoma patients who do not express PD-L1. The investigational combination of eftilagimod alpha and KEYTRUDA® demonstrates promising overall response and disease control rates, expanding treatment options for this challenging cancer type. The data suggests that efti's unique activation of antigen-presenting cells enhances the immune system's response to anti-PD-(L)1 therapies, potentially benefiting patients with negative PD-L1 expression. The study continues to collect and analyze data, with full results expected in H1 CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
-
Rhea-AI Summary
Immutep partners with CHDR for a Phase I trial of IMP761, a LAG-3 agonist antibody to treat autoimmune diseases. The trial will utilize a unique challenge model to assess pharmacological activity. IMP761 aims to restore immune system balance and target autoimmune disease causes. The study is set to begin in mid-CY2024 with 49 healthy volunteers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
management clinical trial
-
Rhea-AI Summary
Immutep receives positive feedback from the Spanish Medicines Agency for the upcoming TACTI-004 registrational trial in metastatic non-small cell lung cancer. The AEMPS supports Immutep moving into a registrational trial in 1L NSCLC and evaluating efti in combination with an anti-PD-1 therapy in a chemotherapy-free regimen or as a triple combination approach that includes chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Immutep Limited announces positive safety and initial efficacy data from the AIPAC-003 trial, showing encouraging results in metastatic breast cancer patients. The combination of 90mg efti with paclitaxel is safe and well-tolerated, with a 50% overall response rate and a 100% disease control rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.06%
Tags
-
Rhea-AI Summary
Immutep Limited (IMMP) reports promising clinical data from various phase II and III trials, including strong overall survival and response rates in non-small cell lung cancer patients. The company is well-financed with a cash balance of A$103.7 million, providing cash runway to early CY 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Immutep Limited (IMM) Announces Enrollment of First Patient in INSIGHT-005 Phase I Trial for Urothelial Carcinoma Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
none
Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces constructive feedback from the Paul-Ehrlich-Institut regarding the planned TACTI-004 Phase III trial of eftilagimod alpha for first line treatment of metastatic non-small cell lung cancer. The PEI is supportive of Immutep moving into a registrational trial in first line NSCLC and evaluating efti in combination with an anti-PD-1 therapy in a chemotherapy-free regimen or as a triple combination approach that includes chemotherapy. Immutep plans to announce its final trial design for TACTI-004 in Q1 of CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none

FAQ

What is the current stock price of Immutep (IMMP)?

The current stock price of Immutep (IMMP) is $1.77 as of April 1, 2025.

What is the market cap of Immutep (IMMP)?

The market cap of Immutep (IMMP) is approximately 260.6M.

What is the core focus of Immutep Ltd?

Immutep primarily focuses on developing immunotherapy products for cancer and autoimmune diseases, leveraging the unique LAG-3 immune mechanism to modulate T cell responses.

How does Immutep utilize LAG-3 technology in its treatments?

The company harnesses LAG-3 technology to regulate the activity of T cells, enabling enhanced immune responses against cancer cells while potentially addressing autoimmune conditions through precise immunomodulation.

What are the key products in Immutep’s development pipeline?

Immutep’s pipeline includes IMP321, a T cell immunostimulatory factor, along with candidates like IMP701 and CVac, which are being developed to address various cancer indications within rigorous clinical settings.

In what ways does Immutep engage in global operations?

While headquartered and predominantly operating from Australia, Immutep maintains a global presence via dual market listings and strategic R&D initiatives, supported by international collaborations and tax incentive programs.

How do Immutep’s strategic partnerships influence its business model?

The company collaborates with major pharmaceutical partners, which enhances its clinical development capabilities, expands its market reach, and reinforces its innovative approach in the competitive biotechnology sector.

What role do research tax incentives play in Immutep’s operations?

Immutep benefits from research tax incentives in both Europe and Australia, which support its R&D expenditures. These incentives validate the company’s commitment to scientific excellence and reinforce its robust clinical development initiatives.

How does Immutep maintain its expertise and trustworthiness in the biotech industry?

Through a strategic focus on advanced immunotherapeutic solutions, adherence to rigorous clinical trial standards, and transparent communication of its scientific and business practices, Immutep demonstrates deep industry expertise and commitment to research integrity.
Immutep

Nasdaq:IMMP

IMMP Rankings

IMMP Stock Data

260.55M
145.44M
0.01%
2.06%
3.46%
Biotechnology
Healthcare
Link
Australia
Sydney